Summary

Agilent Technologies Inc. (Agilent), headquartered in the US, is a provider of instruments, reagents, software, services and consumables for comprehensive laboratory workflows. The company serves biotechnology, pharmaceutical, contract research organizations, contract manufacturing organizations, chemical and energy, environmental and forensics, and food industries. The report, COVID-19 Impact on Agilent Technologies Inc's Revenue and Operations (Medical Devices) presents a deep dive analysis into how Agilent Technologies Inc is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.

Deep dive analysis into how Agilent Technologies Inc is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.

Key Highlights

- The spread of COVID-19 across the globe throughout Q1 2020 has put Agilent Technologies at risk of losing significant revenue.
- Company sales are expected to be disrupted due to the rapid rise of COVID-19 cases in Europe and the US with restricted access to customer facilities.
- However, a universal need for laboratory equipment and high throughput processing to study COVID-19 might result in increased demand for Agilent systems, offsetting revenue losses.
- Agilent Technologies will release their quarterly report on May 21st.

Scope

The report provides a comprehensive analysis of the impact of COVID-19 on Agilent Technologies Inc -
- It provides insights on Agilent Technologies Inc's exposure to the regions and businesses impacted by the COVID-19 outbreak.
- It offers an overview of the company’s revenue impact by region and market for 2020 due to the COVID-19 outbreak.

Reasons to Buy

- An overview of how Agilent Technologies Inc will be affected by the COVID-19 pandemic.